

FOR IMMEDIATE RELEASE

Contact:

Sasha Latypova

(585) 295 7610 X103

sasha.latypova@icardiac.com

iCardiac Expands Sales and Marketing Team

Adds Industry Veteran with Over Two Decades of Cardiovascular Core Lab Experience

Rochester, New York – August 6, 2009 – iCardiac Technologies, Inc., a leader in advanced cardiac safety ECG services and automated QT analysis, announced that it has expanded its sales and marketing team by hiring Susan Boyle as Senior Director of Business Development. Ms. Boyle has over two decades of experience in operations and business development in the clinical research industry, specializing in centralized cardiovascular diagnostic services at a number of leading core laboratories.

“We are excited to welcome Susan to the iCardiac team,” said Sasha Latypova, Executive Vice President. “Susan’s deep client relationships and long history of successfully partnering with clinical pharmacology units will allow iCardiac to better serve its rapidly broadening set of customers and channel relationships.”

“I am proud to join iCardiac at this exciting transformation point in the cardiac core laboratory industry,” said Ms. Boyle. “iCardiac has driven a dramatic shift in the industry by establishing the company as both a leader in Highly Automated QT evaluation as well as advanced techniques for avoiding false positives and negatives in cardiac safety studies.”

About iCardiac Technologies

iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry’s most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac’s analysis service provides drug developers with more precise and cost-effective methods for ECG/QT interval measurements, including Highly Automated QT, which has been validated by pharmaceutical companies and is now used in regulatory submissions as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac’s COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.